Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing the establishment of a wholly owned subsidiary. This aims to expand the endoscope-related business portfolio and strengthen cancer treatment solutions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7733","jir_company_name":"Olympus Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/7733-20260526-01.pdf","jir_short_summary":"Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing the establishment of a wholly owned subsidiary. This aims to expand the endoscope-related business portfolio and strengthen cancer treatment solutions.","jir_summary":"### Overview of the Acquisition\nOlympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., establishing it as a wholly owned subsidiary. BioProtect develops implant technologies that protect healthy tissue during radiation therapy and surgical procedures, with its main product being a biodegradable balloon-type implant. This acquisition will expand the portfolio related to endoscope medical treatments and enhance solutions addressing unmet needs in cancer therapy. The acquisition amount is approximately 43.3 billion yen, with completion scheduled for June 1, 2026.\n\n### Future Outlook and Corporate Strategy\nThis acquisition is part of the management strategy announced in November 2025 and is a key measure in promoting innovation and simplifying business operations. It aims to improve care pathways starting from endoscopes and enhance patient outcomes, contributing to stronger solutions in cancer treatment. The specific impact on future performance is currently under assessment, and additional information will be promptly announced when available.","jir_financial_highlights":"Acquisition Amount: Approximately 43.3 billion yen (Unknown)\nNumber of Shares Acquired: 16,925,621 shares (Unknown)\nBioProtect Capital: 11,451 million yen (Unknown)","jir_category":"","jir_hashtags":"#Olympus, #IR_type_related, #Japan_stock","jir_key_figures":"Acquisition amount: approximately 43.3 billion yen\nNumber of shares acquired: 16,925,621 shares\nBioProtect capital: 11,451 million yen","jir_meta_title":"\u3010Olympus\u3011 Completion of Endoscope-Related Treatment Acquisition\uff5cMay 2026","jir_meta_description":"Olympus has acquired Israel's BioProtect Ltd., expanding its endoscope-related business. This move aims to strengthen cancer treatment solutions and increase corporate value.","jir_og_title":"\u3010Olympus\u3011 Completion of Endoscope Business Expansion Acquisition\uff5cMay 2026","jir_og_description":"Olympus is acquiring shares of BioProtect Ltd. to expand its endoscope-related treatment business and enhance cancer therapy solutions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6918,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-54835","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n